Dossett Lesly A, Riesel Johanna N, Griffin Marie R, Cotton Bryan A
Department of Surgery, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Arch Surg. 2011 May;146(5):565-70. doi: 10.1001/archsurg.2010.313. Epub 2011 Jan 17.
To describe the prevalence of preinjury warfarin use in a large national sample of trauma patients and to define the relationship between preinjury warfarin use and mortality.
Retrospective cohort study.
The National Trauma Databank (7.1).
All patients admitted to eligible trauma centers during the study period; 1,230,422 patients (36,270 warfarin users) from 402 centers were eligible for analysis.
Prevalence of warfarin use and all-cause in-hospital mortality. Multivariate logistic regression was used to estimate the odds ratio (OR) for mortality associated with preinjury warfarin use.
Warfarin use increased among all patients from 2.3% in 2002 to 4.0% in 2006 (P < .001), and in patients older than 65 years, use increased from 7.3% in 2002 to 12.8% in 2006 (P < .001). Among all patients, 9.3% of warfarin users died compared with only 4.8% of nonusers (OR, 2.02; 95% confidence interval [CI], 1.95-2.10; P < .001). After adjusting for important covariates, warfarin use was associated with increased mortality among all patients (OR, 1.72; 95% CI, 1.63-1.81; P < .001) and patients 65 years and older (OR, 1.38; 95% CI, 1.30-1.47; P < .001).
Warfarin use is common among injured patients and its prevalence has increased each year since 2002. Its use is a powerful marker of mortality risk, and even after adjusting for confounding comorbidities, it is associated with a significant increase in death.
描述在一个大型全国性创伤患者样本中受伤前使用华法林的情况,并确定受伤前使用华法林与死亡率之间的关系。
回顾性队列研究。
国家创伤数据库(7.1)。
研究期间所有入住符合条件的创伤中心的患者;来自402个中心的1,230,422名患者(36,270名华法林使用者)符合分析条件。
华法林使用情况及全因院内死亡率。采用多因素logistic回归估计受伤前使用华法林与死亡率相关的比值比(OR)。
所有患者中,华法林的使用从2002年的2.3%增至2006年的4.0%(P <.001),65岁及以上患者中,其使用从2002年的7.3%增至2006年的12.8%(P <.001)。在所有患者中,9.3%的华法林使用者死亡,而非使用者仅为4.8%(OR,2.02;95%置信区间[CI],1.95 - 2.10;P <.001)。在对重要协变量进行调整后,华法林使用与所有患者死亡率增加相关(OR,1.72;95%CI,1.63 - 1.81;P <.001),在65岁及以上患者中也是如此(OR,1.38;95%CI,1.30 - 1.47;P <.001)。
华法林在受伤患者中使用普遍,自2002年以来其使用率逐年上升。其使用是死亡风险的有力标志物,即使在对混杂的合并症进行调整后,仍与死亡显著增加相关。